Expert Opinion on Emerging Drugs

Papers
(The TQCC of Expert Opinion on Emerging Drugs is 7. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-11-01 to 2025-11-01.)
ArticleCitations
New drugs targeting calcitonin gene-related peptide for the management of migraines27
Emerging and traditional 5-α reductase inhibitors and androgen receptor antagonists for male androgenetic alopecia27
Emerging immune tolerance therapies for neuromyelitis optica spectrum disorder26
Combined chemo-immunotherapy in advanced non-small cell lung cancer: feasible in the elderly?20
A review of phase II and III drugs for the treatment and management of endometriosis18
Emerging drugs for the treatment of acne: a review of phase 2 & 3 trials16
Future treatments for myelin oligodendrocyte glycoprotein antibody-associated disease: the clinical trial landscape15
Emerging medicines to improve the basic defect in cystic fibrosis15
Muscarinic M1 and M4 agents as treatments for schizophrenia: what do they do and who do they do it for?15
Evolving role of VIADISC for chronic low back and discogenic pain: a narrative review15
How can we prevent diarrhea induced by systemic treatments in oncological patients? An evaluation of phase II trials15
Emerging biological treatments for asthma12
Emerging drugs for the treatment of progressive familial intrahepatic cholestasis: a focus on phase II and III trials11
Existing and emerging therapies for the treatment of invasive candidiasis and candidemia11
Newly emerging tyrosine kinase inhibitors for the treatment of neuroendocrine neoplasms11
Emerging injectable therapies for osteoarthritis11
Emerging drugs for the treatment of herpetic keratitis9
A review of emerging factor XI inhibitors9
Emerging drugs for the treatment of paroxysmal nocturnal hemoglobinuria8
Emerging treatment for Sjögren’s disease: a review of recent phase II and III trials8
Expert opinion on emerging drugs for lung chronic graft-versus-host disease8
Cannabinoid treatment for the symptoms of autism spectrum disorder8
Emerging drugs in phase II and III clinical development for the treatment of alcohol use disorder7
Emerging antiviral therapies and drugs for the treatment of influenza7
Novel and emerging drugs for the treatment of Crohn’s disease: a review of phase II and III trials7
Recent advances in immune-based approaches for the treatment of esophagogastric cancer7
ONC201 (Dordaviprone): review of evidence to date in diffuse midline glioma, hope or hype?7
Correction7
How will tovorafenib change our treatment of pediatric low-grade glioma?7
Emerging drugs for antibody-mediated rejection after kidney transplantation: a focus on phase II & III trials7
Emerging monoclonal antibody therapies in the treatment of metastatic urothelial carcinoma7
Emerging tyrosine kinase inhibitors for head and neck cancer7
A comprehensive review of phase 2/3 trials in osteoarthritis: an expert opinion7
0.30682420730591